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NEWS AND VIEWS
Meeting report on the first Sino-Dutch 
symposium on oncology
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Abstract 
On October 31, 2015, the first Sino-Dutch symposium on oncology was organized in Guangzhou (China). The sym-
posium revealed similarities between Chinese and Dutch efforts to improve the care of tumor patients and to create 
enhanced insight into the nature of cancers. In particular, it became evident for some types of cancer that immuno-
therapy should focus on counteracting interleukin-17-associated immunity and targeting cancer stroma. Targeting 
specific cancer microenvironment and stroma also opens new therapeutic options, including the use of radio-active 
theranostics and live tumor imaging-guided surgeries.
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Background
Many societies in the present era are characterized by 
the unprecedented phenomenon of population aging, 
which imposes substantial new challenges to heath care. 
Perhaps the foremost of these challenges is an increased 
burden of tumors; and, indeed, in many societies, cancer 
has become the main cause of death. Hence, healthcare 
systems are under substantial pressure to develop novel 
modalities aimed at improving the diagnosis and treat-
ment of tumors, both with respect to clinical outcome 
and patient quality of life. This issue is particularly true 
for both China and Europe, which are both subjected to 
substantial population aging, especially when compared 
with, for instance, the United States of America or India. 
It follows that Chinese and European health institutions 
should seek collaboration to develop novel avenues for 
combating tumors, as both face relatively similar chal-
lenges. Accordingly, collaboration was initiated between 
the Sun Yat-sen University Cancer Center (SYSUCC, 
one of the top cancer centers in China) and the Erasmus 
Medical Center (Erasmus MC, the largest university hos-
pital in the Netherlands) on all aspects of clinical cancer 
care and research. This relationship was recently formal-
ized through the signing of a mutual memorandum of 
understanding between the Erasmus MC and SYSUCC 
(Fig.  1). The collaboration was initiated by Prof. Chao-
Nan (Miles) Qian (Vice President of SYSUCC) and Prof. 
Dr. Jaap Verweij (Dean of the Erasmus MC Executive 
Board). Florence Sand (SYSUCC) and Raoul Tan (Eras-
mus MC) were instrumental in arranging the adminis-
trative and logistic details involved. This collaboration 
promises to provide great oncological research synergy at 
both institutions and should prove important for the field 
in general. The unusual potential of the collaboration 
became evident at the first Sino-Dutch symposium on 
oncology that was held on October 31, 2015 in Guang-
zhou, in which eminent scientists from both institutions 
presented their work (Fig. 2), which in conjunction pro-
duced important new insights. This meeting report aims 
to convey the progress reached during the symposium to 
a larger audience.
Thoracic cancer
Thoracic cancers (e.g., esophageal cancer, lung cancer, 
breast cancer) represent the most common cancer types 
not only in China but also in the patient population of 
the Erasmus MC. Early detection and intervention can 
substantially contribute to clinical outcome of such can-
cers. For example, proton pump inhibition therapy can 
substantially reduce the risk for malignant progression of 
esophageal cancer [1]. In my presentation (Maikel Pep-
pelenbosch; Erasmus MC), I highlighted the importance 
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of biochemical characterization of both premalignant 
and malignant tissues for guiding prevention as well as 
treatment of such cancers, and this plan was echoed well 
by data presented by Ling Cai (SYSUCC). He demon-
strated that detecting mutations of the epidermal growth 
factor receptor (EGFR) in non-small cell lung cancer 
does not provide significant guidance for predicting the 
efficacy of EGFR tyrosine kinase inhibitors (TKIs), espe-
cially when combined with whole body radiation therapy. 
Remarkably, in the latter presentation, data were shown 
that the clinical efficacy of TKIs was independent of the 
actual mutation (either in the receptor tail or loss of the 
extracellular domain), and this observation corresponded 
well with my own earlier finding that kinase activity in 
thoracic (pre-)cancerous lesions was relatively independ-
ent of the underlying mutation status [2]. Similarly, Dr. 
Lan-Jun Zhang (SYSUCC) presented data that attempted 
to identify genetic variations in pulmonary lymphoe-
pithelioma, but the findings were not conclusive. Taken 
together, these findings suggest that the current empha-
sis on next-generation sequencing of thoracic cancer 
samples for guiding personalized medicine may prove 
to be disappointing. This conclusion highlights how new 
insights can emerge from bilateral conferences like the 
one reported here.
The role of the tumor microenvironment
Cases on the role of the tumor microenvironment were 
presented by Dr. Limin Zheng (SYSUCC) and Dr. Reno 
Debets (Erasmus MC), who both focused on the role 
of the immune system in combating tumors. Dr. Zheng 
presented his data on the microenvironment of hepa-
tocellular carcinoma, showing that this environment is 
characterized by suppressive macrophages, which appear 
Th17-polarized, and thus are poor interferon γ secretors. 
This microenvironment, although highly pro-inflam-
matory, is not permissive for cytotoxic T cell responses, 
enabling a growing tumor to evade immunosurveillance. 
Alone, these data are highly interesting, as they mecha-
nistically explain the well-established capacity of hepa-
tocellular carcinoma to escape attack by the immune 
system, even in the context of copious immunoreactiv-
ity towards tumor antigens in patients with this type of 
cancer [3]. However, in context of the work presented by 
Dr. Reno Debets, these data acquire additional compel-
ling relevance. Dr. Debets has a very efficient platform for 
engineering enhanced T cell receptors, which can effi-
ciently attack a broad range of tumor types. It has often 
been suggested that such approaches would benefit from 
co-administration with ipililumimab, a biological medi-
cine that counteracts regulatory activity. A realization 
emerged in the audience from Dr. Zheng’s prior presen-
tation that, at least for hepatocellular carcinoma, anti-
interleukin-17 antibodies (currently used for treating 
multiple sclerosis but not tumors) may be a more promis-
ing treatment strategy.
Novel approaches to cancer eradication
Interestingly, the specific microenvironment created by 
tumors to escape anti-cancer immunity may also prove 
Fig. 1 Prof. Dr. Jaap Verweij (Dean of the Erasmus Medical Center 
executive board; left in the front) and Prof. Chao-Nan (Miles) Qian 
(Vice President of the Sun Yat-sen University Cancer Center; right in 
the front) congratulate each other with the signing of the Sino-Dutch 
collaboration agreement between these two institutions.  From left 
to right in the back: Ms. Yao Xu (Deputy Director, Office of Interna-
tional Cooperation and Exchange, Sun Yat-sen University), Prof. Limin 
Zheng, (Biotherapy Center, Sun Yat-sen University Cancer Center), Mr. 
Peter Boostma (Health, Welfare and Sport Counselor at Embassy of 
the Kingdom of the Netherlands in China), Mrs. Marjo Crompvoets 
(Consul General of the Kingdom of the Netherlands in Guangzhou)
Fig. 2 Some of the speakers at the first Sino-Dutch Symposium 
on Oncology. From left to right: Dr. Shuang Liao, Dr. Yu-Jia Zhu, Prof. 
Zhen-Ffeng Zhang, Prof. Jean-Phille Pignol, Prof. Marion de Jong, Prof. 
Jaap Verweij, Prof. Chao-Nan (Miles) Qian (in the front), Prof. Timo ten 
Hagen (in the back), Prof. Jose Hardillo, Prof. Clemens Löwik, Mr. Raoul 
Tan, Prof. Reno Debets, Mrs. Gonny Pasaribu, Prof. Li-Wu Fu, and Mr. 
Jingmin Kan (Assistant Counsellor for Science and Technology at 
Embassy of the Kingdom of the Netherlands in China)
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to be an Achilles heel for these cancers. Such specific 
microenvironment may result in the strong expres-
sion of peptide receptors with an otherwise much more 
restricted expression. As Dr. Marjon de Vos (Erasmus 
MC) showed in her exciting presentation, such peptide 
receptors are excellent targets for therapeutic peptide 
radionucleotides, which upon binding to their cognate 
ligands can kill cancer cells by emitting ionizing radiation 
[4]. Intriguing proof-of-principle examples were pro-
vided by Dr. de Vos, who showed that down-regulation 
of the receptors involved was probably incompatible with 
the necessity to maintain a specific microenvironment 
to escape immunosurveillance. As shown by Dr. Zheng, 
it is possible to significantly improve clinical outcomes. 
Indeed, the necessity of a specific tumor microenviron-
ment was also highlighted by various other presenta-
tions. For example, Dr. Clemens Löwik (Erasmus MC) 
presented examples of highly advanced imaging technol-
ogy capable of visualizing mesenchymal stem cells and 
showed important constituents of a variety of cancers. 
Such novel imaging modalities are likely to contribute to 
better care, as they allow for detection of cancer cells in 
the operation theater, allowing surgeons to ensure that 
the entire cancer is resected. This notion was further sup-
ported by data from Dr. José Angelito Ugalde Hardillo 
(Erasmus MC), who showed that tumor samples have 
specific Raman spectra. In the future, this technique may 
provide further specificity and provide real-time guid-
ance to the surgeons during operation procedures.
Drug delivery
Therapeutic efficacy, however, either through novel drugs 
or by conventional drugs, critically depends on the effi-
ciency of drug delivery. New insights emerged through 
the synergy generated in this Sino-Dutch symposium. Dr. 
Timo ten Hagen (Erasmus MC) presented data obtained 
with intravital microscopy that conventional liposo-
mal delivery of doxorubicin to tumor cells lacks efficacy 
because of slow release of the drug from the liposome, a 
problem potentially further compounded by liposomal 
processing by the tumor cells. The discovery of Dr. Xin 
Mei (SYSUCC), also employing live imaging, that glio-
blastoma cells display vascular mimicry and can appar-
ently create potentially functional blood vessels was also 
presented at this symposium. Cancer cells in general 
benefit from the presence of blood vessels, and for clear 
cell renal cell carcinoma, anti-angiogenic therapy is even 
the treatment of choice [4]; however, efficient blood sup-
ply also provides a route for drug delivery. This notion 
critically depends on the functionality of these blood ves-
sels [5]. The use of tissue factors as indicator molecules 
to confirm or exclude the functionality of the vessel-like 
structures involved was extensively elaborated on during 
the ensuing discussion, further illustrating the value of 
this type of symposium.
Conclusions
The first Sino-Dutch symposium was unusually produc-
tive with respect to generating new insight into how 
cancer in aging societies can be approached. This initial 
success augurs very well for closer collaboration between 
the Erasmus MC and SYSUCC. As both centers now 
develop clinical implementation of proton therapy (pres-
entation of Dr. Jean-Philipe Pignol) for tumors, further 
benefits and synergies will likely continue to emerge from 
this collaboration.
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